The landscape of pharmaceutical mergers and acquisitions (M&As) is fraught with complexity and risk, particularly when it comes to research and development (R&D) due diligence. Here, we explore how Cyntegrity’s MyRBQM® Portal can provide a comprehensive solution for R&D due diligence professionals navigating the M&A process.

The Need for Robust R&D Due Diligence

Pharmaceutical M&As involve a myriad of activities, each with its unique set of risks. These activities often span different stages of the clinical trial process, from preclinical research to late-stage trials and commercialization.

Below is a table summarizing typical M&A activities, when they occur, and the associated risks:

M&A Activity Clinical Trial Phase Associated Risk
Drug Patent Acquisition Preclinical/Phase I Risk of early failure, long duration till market
In-licensing Phase II/Phase III Risk of failure in larger, more complex trials
Partnering Late Phase III/Commercialization Risk of regulatory rejection, market acceptance

It’s clear that managing these risks requires a robust, data-driven approach. This is where MyRBQM Portal steps in.

The MyRBQM Portal Advantage: Real-Time Monitoring and Predictive Analytics

Cyntegrity’s MyRBQM Portal, a risk-based quality management platform, provides several key advantages for R&D due diligence. From centralized risk management to predictive analytics, it offers tools designed to streamline the due diligence process and aid in decision-making.

Centralized Risk Management: MyRBQM Portal offers a unified view of all risk-related aspects of clinical trials. This centralized approach aids in regulatory compliance, including the detection of potential fraud and misconduct. It allows you to monitor the entire portfolio of clinical trials in real-time. The portal collects and consolidates all the critical Key Risk Indicator (KRI) data, enabling rapid assessment of progress and identification of potential risks, including irregularities that may suggest fraudulent activities.

Fraud and Misconduct Detection: One of the critical advantages of the MyRBQM Portal is its ability to help detect potential fraud and misconduct. Through its comprehensive assessment of KRIs and sophisticated analytics, the platform can identify patterns and anomalies that might indicate fraudulent data or unethical practices. This early detection capability can be crucial in preventing significant financial and reputational damage.

Comprehensive Risk Assessment: The platform evaluates critical KRIs such as enrollment rates, data inconsistencies, or protocol deviations. This not only helps identify potential issues early, including signs of fraud or misconduct, but also forecasts the likelihood of achieving specific milestones through its predictive analytics module. Wouldn’t you want to know if you hit your targets in 6-12 months? Or if there are any red flags to watch out for? With MyRBQM Portal, you can.

Streamlined TMF Inspection Readiness: MyRBQM Portal ensures that the trial master files (TMFs) are compliant with regulatory standards, thus reducing post-acquisition compliance issues. It also aids in maintaining the integrity of TMFs, contributing to the prevention and detection of any fraudulent activity.

Transparent Risk Communication: The platform’s reporting features allow for clear communication of potential risks, including fraud or misconduct, and strategies to mitigate them. With comprehensive reports, you can have actionable data at your fingertips, aiding in effective communication and decision-making.

Enhanced Decision-Making: With advanced analytics and data-driven insights, decision-making becomes more informed and effective. The platform not only provides a current status report of clinical trials but also predicts their future trajectory and potential pitfalls, including potential risks of fraud and misconduct. This enables you to make well-informed decisions about investment, risk mitigation, and potential returns.

Diligence should be tech-enabled. Many processes in pharma companies are standardized by enterprise resource planning (ERP) and cloud-based computing. Unfortunately, the diligence process usually isn’t one of them. Instead, it often remains an ad hoc experience with cross-functional collaboration happening through brute force rather than by design. In our experience, successful biotech deals are increasingly centered around real-time insights delivered through a tech-enabled process. (Source: PwC | 8 critical success factors for biotech deals)

MyRBQM Portal and Milestone-Based Payments

Milestone-based payments are a common feature in life sciences M&A, licensing, and collaboration deals. These payments are tied to the achievement of specific development, regulatory, or commercial milestones, which helps distribute the financial risk associated with the product and incentivize performance.

In milestone-based payment approaches MyRBQM Portal provides significant value:

  • Risk Mitigation: Real-time monitoring of performance KRIs enables proactive risk management, thereby distributing the financial risk associated with drug development.
  • Valuation Gap Bridging: Tracking progress towards milestones helps bridge the valuation gap between buyer and seller.
  • Incentivizing Performance: By monitoring achievement of development, regulatory, or commercial milestones, the acquired company is incentivized to focus on product advancement.
  • Reflecting Value Creation: MyRBQM Portal aligns the payment structure with the product’s value creation over time, ensuring a fair financial arrangement.

With few IPOs and follow-on public fundings expected during at least the first half of 2023, biotechs are becoming more willing product licensers, collaborators – and even sellers. They will need strong data to get the terms they want. Up-front cash and near-term milestones take priority over downstream value. (Source: Deals In 2023: Partnerships And Modest M&A)


In the intricate world of pharma M&As, effective R&D due diligence, including the detection and prevention of potential fraud and misconduct, is paramount. The innovative MyRBQM Portal by Cyntegrity offers a comprehensive solution to navigate this landscape efficiently, armed with data-driven insights and proactive risk management strategies. It provides a unique blend of technology and analytics, enabling R&D due diligence professionals to make more informed decisions and successfully navigate the intricacies of clinical trials during M&A processes.

With its real-time portfolio monitoring, predictive analytics, transparent risk communication, and advanced fraud detection capabilities, the MyRBQM Portal provides valuable foresight and control. These are essential for managing the uncertainties inherent in pharma M&As, including those related to potential fraud and misconduct. Whether it’s about hitting milestones in 6-12 months, ensuring TMF inspection readiness, or spotting early signs of irregularities, the platform equips professionals with the tools they need to mitigate risk and maximize returns on investment.

MyRBQM Portal helps bridge the gap between risk and reward, turning potential obstacles into opportunities for success. It not only aids in managing clinical trial risks but also plays a crucial role in upholding ethical standards in clinical research. Don’t leave your M&A outcomes to chance; let Cyntegrity’s MyRBQM Portal guide your path to strategic growth, competitive advantage, and integrity in the pharma industry. Contact us today to learn more about how our platform can support your R&D due diligence efforts.